Short biography
Laura Soucek graduated in Biological Sciences at the University La Sapienza, Rome (Italy) in 1996. She was then awarded her PhD in Genetics and Molecular Biology in 2001. She was a postdoctoral fellow and Assistant Researcher in Dr. Gerard Evan’s laboratory at the University of California San Francisco (UCSF, USA) until 2011. Since then, she has been leading the Models of Cancer Therapies Laboratory at the Vall d’Hebron Institute of Oncology (VHIO), in Barcelona, Spain, where she became Director of the Preclinical and Translational Research Program in 2022 and of the Experimental Therapeutics Research Program in 2024. She is ICREA Research Professor and Associate Professor at the Universidad Autónoma de Barcelona (UAB). Laura is a key opinion leader in Myc inhibition strategies, as well as founder and CEO of Peptomyc S.L., a spin off company that aims at treating cancer with anti-Myc peptides. Peptomyc lead compund, OMO-103, successfully completed a Phase I clinical trial in 2022.
